Neurocrine biosciences announces top-line results from phase ii interact study evaluating luvadaxistat (nbi-1065844) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia (cias)

San diego, march 2, 2021 /prnewswire/ -- neurocrine biosciences (nasdaq: nbix) today announced that investigational drug luvadaxistat (nbi-1065844/tak-831) did not meet its primary endpoint in the phase ii interact study in adults with negative symptoms of schizophrenia, as measured by...
NBIX Ratings Summary
NBIX Quant Ranking